Aytu Biopharma (AYTU) Current Leases (2019 - 2022)

Aytu Biopharma (AYTU) posted quarterly Current Leases of $1.2 million for Q1 2022, up 2.56% quarter-over-quarter from $1.2 million in Q4 2021.

Aytu Biopharma (AYTU) Current Leases (2019 - 2022) Analysis & Trends

Aytu Biopharma (AYTU) has reported Current Leases for 4 consecutive years, with $1.2 million the latest figure, recorded in Q1 2022.

In Q1 2022, Current Leases changed N/A year-over-year to $1.2 million; the TTM figure through Mar 2022 stood at $1.2 million (changed N/A YoY), while the FY2021 annual figure was $940000.0, up 213.33% from the prior year.
Current Leases grew to $1.2 million in Q1 2022 per AYTU's latest filing, from $1.2 million in the prior quarter.
Across five years, Current Leases topped out at $1.2 million in Q1 2022 and bottomed at $79362.0 in Q3 2019.
Historically, Current Leases has averaged $534907.6 across 4 years, with a median of $294619.0 in 2020.
Annual changes were most pronounced in 2020 — Current Leases climbed 21.16% — and 2021, when it soared 1069.92%.
Aytu Biopharma's Current Leases stood at $82755.0 in 2019, then gained by 21.16% to $100263.0 in 2020, then jumped by 1069.92% to $1.2 million in 2021, then grew by 2.56% to $1.2 million in 2022.
Business Quant data shows AYTU's Current Leases at $1.2 million in Q1 2022, $1.2 million in Q4 2021, and $1.1 million in Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Leases (Qtr)
1	Haleon	43.91 Bn	42.95 Bn	-	-
2	Teva Pharmaceutical Industries	42.98 Bn	39.32 Bn	2.15 Bn	-
3	Zoetis	31.53 Bn	29.86 Bn	1.05 Bn	-
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	-
5	United Therapeutics	22.16 Bn	19.49 Bn	683.80 Mn	-
6	Viatris	18.74 Bn	17.85 Bn	1.46 Bn	-
7	Neurocrine Biosciences	15.51 Bn	15.12 Bn	935.80 Mn	-
8	Elanco Animal Health	11.76 Bn	11.23 Bn	798.00 Mn	-
9	Dr Reddys Laboratories	10.12 Bn	9.95 Bn	-	-
10	Aytu Biopharma	24.60 Mn	-2.12 Mn	7.60 Mn	-

Download Data